DNA in the 13F filings
Ginkgo Bioworks Holdings Inc · CUSIP 37611X209
- Quarter end
- 31 Mar 2025
- the date the book describes
- Filed
- 15 May 2025
- latest of these filings; the earliest 7 May 2025
- Managers listing it
- 4
- at least, of 95 tracked, among listed positions
- Comparable managers
- 95
- filed both Q4 2024 and Q1 2025; 4 listed it in both
- Shares listed
- 7,500,673
- combined, among listed positions
- Reported value
- $43m
- combined, at the quarter end
Among the 95 comparable managers: 1 buyer (opened or added shares) and 1 seller (trimmed or exited), at least, among listed positions. Their net change in shares was +189,855.
Managers listing DNA in Q1 2025
4 of 4 holders
| Action | Filing | |||||
|---|---|---|---|---|---|---|
| Viking Global Investors LP | 3,577,128 | $20m | 0.06% | Held | 0 | 15 May 2025 (the filing on sec.gov) |
| Baillie Gifford & Co | 3,350,891 | $19m | under 0.1% | Trimmed | -6,495 | 7 May 2025 (the filing on sec.gov) |
| PDT Partners LLC | 385,153 | $2.2m | 0.16% | Added | +196,350 | 15 May 2025 (the filing on sec.gov) |
| Glenview Capital Management LLC | 187,501 | $1.1m | under 0.1% | Held | 0 | 15 May 2025 (the filing on sec.gov) |
Largest increases and reductions, by shares
Increases
- PDT Partners LLCexisting position · 385,153 shares now+196,350
Reductions
- Baillie Gifford & Coexisting position · 3,350,891 shares now-6,495
New positions and exits
New (0)
No new position among listed positions.
Exited (0)
No exit shown by a manager’s own filing.
Ownership over time
Tracked managers listing it, at least.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q3 2024 | 5 | $62m | 5 | 0 |
| Q4 2024 | 4 | $72m | 1 | 3 |
| Q1 2025 | 4 | $43m | 1 | 1 |
| Q2 2025 | 4 | $80m | 0 | 3 |
| Q3 2025 | 5 | $104m | 1 | 2 |
| Q4 2025 | 4 | $52m | 16 | 7 |
| Q1 2026 | 2 | $37m | 9 | 16 |
| Q2 2026 | 3 | $61m | 11 | 10 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
DNA and GILD →DNA and AMGN →DNA and ARGX →Choose a stock to compare with DNA →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own DNA, latest filings →Back to the 13F Explorer →